Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, ACTIVE- AND PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP STUDY OF THE ANALGESIC EFFECTS OF TANEZUMAB IN ADULT PATIENTS WITH CHRONIC LOW BACK PAIN
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a monoclonal antibody directed against human nerve growth factor.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Manual / Manipulative Therapy (M/MT) | Intervention Type: PROCEDURE; Name: Manual / Manipulative Therapy (M/MT); Assigned to Arm(s): 2
B: Arm Label: Tanezumab 20 mg IV; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab 20 mg IV, Drug: Placebo for naproxen | Arm Label: Tanezumab 10 mg IV; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab 10 mg IV, Drug: Placebo for naproxen | Arm Label: Tanezumab 5 mg IV; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab 5 mg IV, Drug: Placebo for naproxen | Arm Label: Naproxen; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo for tanezumab, Drug: Naproxen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for tanezumab, Drug: Placebo for naproxen | Intervention Type: BIOLOGICAL; Name: Tanezumab 20 mg IV; Assigned to Arm(s): Tanezumab 20 mg IV | Intervention Type: DRUG; Name: Placebo for naproxen; Assigned to Arm(s): Tanezumab 20 mg IV | Intervention Type: BIOLOGICAL; Name: Tanezumab 10 mg IV; Assigned to Arm(s): Tanezumab 10 mg IV | Intervention Type: DRUG; Name: Placebo for naproxen; Assigned to Arm(s): Tanezumab 10 mg IV | Intervention Type: BIOLOGICAL; Name: Tanezumab 5 mg IV; Assigned to Arm(s): Tanezumab 5 mg IV | Intervention Type: DRUG; Name: Placebo for naproxen; Assigned to Arm(s): Tanezumab 5 mg IV | Intervention Type: BIOLOGICAL; Name: Placebo for tanezumab; Assigned to Arm(s): Naproxen | Intervention Type: DRUG; Name: Naproxen; Assigned to Arm(s): Naproxen | Intervention Type: BIOLOGICAL; Name: Placebo for tanezumab; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo for naproxen; Assigned to Arm(s): Placebo
C: Arm Label: Tramadol Hydrochloride (HCl)/acetaminophen; Type: EXPERIMENTAL; Interventions: Drug: Tramadol HCl/acetaminophen Extended Release | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tramadol HCl/acetaminophen Extended Release; Assigned to Arm(s): Tramadol Hydrochloride (HCl)/acetaminophen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tramadol HCl/acetaminophen Extended Release; Assigned to Arm(s): Tramadol Hydrochloride (HCl)/acetaminophen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Back school; Type: EXPERIMENTAL; Interventions: Behavioral: back school | Arm Label: back school; Type: EXPERIMENTAL; Interventions: Behavioral: back school | Intervention Type: BEHAVIORAL; Name: back school; Assigned to Arm(s): Back school, back school

Answer: B